Inmed pharmaceuticals announces $5.2 million private placement and preferred investment option exercise priced at-the-market under nasdaq rules

Vancouver, british columbia--(newsfile corp. - october 24, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has entered into definitive agreements for the issuance and sale of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof) and associated preferred investment option in a private placement priced at-the-market under nasdaq rules (the "private placement"). the company has also entered into a definitive agreement with respect to certain of its outstanding preferred investment options issued in november 2022 and exercisable for 3,272,733 common shares, in the aggregate, to exercise such preferred investment options for cash at a reduced exercise price of $0.83 per share, in exchange for unregistered new preferred investment options to purchase up to 6,545,466 common shares (the "preferred investment option exercise" and, collectively with the private placement, the "offerings").
INM Ratings Summary
INM Quant Ranking